Hemophilia A and B Recombinant Factor Replacement Therapy - US Drug Forecast and Market Analysis to 2024

Description: Hemophilia A and B Recombinant Factor Replacement Therapy - US Drug Forecast and Market Analysis to 2024

Summary

Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.

The US is the largest global hemophilia market, due to high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. This market growth will be driven by increasing rates of prevalent cases of hemophilia A and B, and increasing uses of recombinant replacement factors in hemophilia A and B patients over the forecast period.

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in US.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis and Quality of Life
3.2 Symptoms
3.2.1 Hemophilia A and B
3.2.2 Inhibitors
4 Disease Management
4.1 Treatment Overview
4.1.1 Hemophilia A and B Diagnosis
4.1.2 Hemophilia A and B Treatment
4.1.3 Diagnosis of Inhibitors
4.1.4 Treatment of Inhibitors
4.2 US
4.2.1 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Hemophilia A
5.3.1 Advate (Octocog Alfa)
5.3.2 Kogenate FS/Helixate FS (Octocog Alfa)
5.3.3 Xyntha/ReFacto AF (Moroctocog Alfa)
5.3.4 Recombinate (Octocog Alfa)
5.3.5 Eloctate (Efmoctocog Alfa)
5.3.6 NovoEight (Turoctocog Alfa)
5.3.7 Nuwiq (Simoctocog Alfa)
5.4 Product Profiles - Hemophilia B
5.4.1 BeneFIX (Nonacog Alfa)
5.4.2 Alprolix (Eftrenonacog Alfa)
5.4.3 Rixubis (Nonacog Gamma)
5.4.4 IXinity (Trenonacog Alfa)
5.5 Product Profiles - Hemophilia A and B with Inhibitors
5.5.1 NovoSeven RT (Eptacog Alfa)

6 Unmet Need and Opportunity

6.1 Overview

6.2 Opportunity Analysis

6.2.1 Longer-Lasting Recombinant Factors

6.2.2 Lower-Cost Recombinant Replacement Therapies

6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients

6.2.4 More Convenient Drug Administration

6.3 Unmet Needs Gap Analysis

6.3.1 Long-Acting FVIII Replacement Therapies

6.3.2 Gene Therapy Treatments for Hemophilia A and B

7 Pipeline Assessment

7.1 Overview

7.2 Late-Stage Development Candidates - Hemophilia A

7.2.1 Kovaltry (Octocog Alfa; BAY 81-8973)

7.2.2 Adynovate (BAX-855)

7.2.3 BAY 94-9027 (Damocctocog Alfa Pegol)

7.2.4 N8-GP (Turoctocog Alfa Pegol)

7.2.5 CSL-627 (rFVIII-SC)

7.2.6 GreenGene F (Berocctocog Alfa; GC1101C)

7.3 Late-Stage Development Candidates - Hemophilia B

7.3.1 CSL-654 (rIX-FP; Albutrepenonacog Alfa)

7.3.2 N9-GP (NN-7999; Nonacog Beta Pegol)

7.4 Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents (Patients with Inhibitors)

7.4.1 BAX-817 (rFVIIa BI)

7.4.2 LR-769 (rhFVIIa)

7.4.3 CSL-689 (rVIIa-FP)

7.5 Promising Drugs in Early-Stage Development

7.5.1 Alternative Coagulation Promoters

7.5.2 Gene Therapies

8 Market Outlook

8.1 US
Table 6: Advate SWOT Analysis, 2015
Table 7: Global Sales Forecast ($m) for Advate, 2014-2024
Table 8: Product Profile - Kogenate FS/Helixate FS
Table 9: Kogenate FS/Helixate FS SWOT Analysis, 2015
Table 10: Global Sales Forecast ($m) for Kogenate FS/Kogenate Bayer, 2014-2024
Table 11: Global Sales Forecast ($m) for Helixate FS/Helixate NexGen, 2014-2024
Table 12: Product Profile - Xyntha/ReFacto AF
Table 13: Xyntha/ReFacto AF SWOT Analysis, 2015
Table 14: Global Sales Forecast ($m) for Xyntha/ReFacto AF, 2014-2024
Table 15: Product Profile - Recombinate
Table 16: Recombinate SWOT Analysis, 2015
Table 17: Global Sales Forecast ($m) for Recombinate, 2014-2024
Table 18: Product Profile - Eloctate
Table 19: Eloctate SWOT Analysis, 2015
Table 20: Global Sales Forecast ($m) for Eloctate, 2014-2024
Table 21: Product Profile - NovoEight
Table 22: NovoEight SWOT Analysis, 2015
Table 23: Global Sales Forecast ($m) for NovoEight, 2014-2024
Table 24: Product Profile - Nuwiq
Table 25: Nuwiq SWOT Analysis, 2015
Table 26: Global Sales Forecast ($m) for Nuwiq, 2014-2024
Table 27: Product Profile - BeneFIX
Table 28: BeneFIX SWOT Analysis, 2015
Table 29: Global Sales Forecast ($m) for BeneFIX, 2014-2024
Table 30: Product Profile - Alprolix
Table 31: Alprolix SWOT Analysis, 2015
Table 32: Global Sales Forecast ($m) for Alprolix, 2014-2024
Table 33: Product Profile - Rixubis
Table 34: Rixubis SWOT Analysis, 2015
Table 35: Global Sales Forecast ($m) for Rixubis, 2014-2024
Table 36: Product Profile - IXinity
Table 69: Global Sales Forecast ($m) for N9-GP, 2014-2024
Table 70: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2015
Table 71: Product Profile - BAX-817
Table 72: BAX-817 SWOT Analysis, 2015
Table 73: Global Sales Forecast ($m) for BAX-817, 2014-2024
Table 74: Product Profile - LR-769
Table 75: LR-769 SWOT Analysis, 2015
Table 76: Global Sales Forecast ($m) for LR-769, 2014-2024
Table 77: Product Profile - CSL-689
Table 78: CSL-689 SWOT Analysis, 2015
Table 79: Global Sales Forecast ($m) for CSL-689, 2014-2024
Table 80: Alternative Coagulation Promoters - Early-Stage Pipeline, 2015
Table 81: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2015
Table 82: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the US, 2014-2024
Table 83: Key Events Impacting Sales for Hemophilia A and B in the US, 2014-2024
Table 84: US Hemophilia A and B Market - Drivers and Barriers, 2014-2024
Table 85: Key Launch Dates
Table 86: Physicians Surveyed

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2014-2024
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia B, 2014-2024
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents for Hemophilia A and B Patients with Inhibitors, 2014-2024
Figure 4: Sales for Hemophilia A and B recombinant therapies in the US by Drug Class, 2014-2024

Ordering:


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Hemophilia A and B Recombinant Factor Replacement Therapy - US Drug Forecast and Market Analysis to 2024
Web Address: http://www.researchandmarkets.com/reports/3783649/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
<th>Discount Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3996</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 11239</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 4995 - Until Jun 02nd 2017</td>
<td>USD 14985 - Until Jun 02nd 2017</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp